CureVac
Meryem Chennan is a Senior Manager Regulatory Affairs at CureVac, bringing with their a wealth of experience in regulatory affairs from previous roles at various companies such as Dr. Franz Köhler Chemie GmbH, Siegfried Holding AG, and Vetter Pharma. With a PhD in Virologie and Phytomedizin - Agrarwissenschaft from University of Hohenheim, Meryem also holds a Diplom-Ingenieurin in Agrarwissenschaft und Phytomedizin from Institut agronomique et vétérinaire Hassan II. Meryem's career includes roles as a Wissenschaftlerin at Universität Hohenheim and as a Mitarbeiterin at Labor für medizinische Diagnostik.
This person is not in the org chart
This person is not in any offices
CureVac
8 followers
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.